Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
29.69 GBX | -1.04% | -8.65% | +91.54% |
Apr. 18 | Renalytix chief business officer to become president | AN |
Apr. 18 | Renalytix Names Chief Business Officer as President | MT |
Financials (USD)
Sales 2024 * | 4M | Sales 2025 * | 18M | Capitalization | 48.19M |
---|---|---|---|---|---|
Net income 2024 * | -35M | Net income 2025 * | -26M | EV / Sales 2024 * | 12 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.68 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 102 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.43% |
Latest transcript on Renalytix Plc
1 day | -2.67% | ||
1 week | -10.15% | ||
Current month | -12.84% | ||
1 month | -17.75% | ||
3 months | +159.56% | ||
6 months | -38.53% | ||
Current year | +88.39% |
Managers | Title | Age | Since |
---|---|---|---|
James McCullough
FOU | Founder | 56 | 18-03-14 |
James Sterling
DFI | Director of Finance/CFO | 54 | 18-03-14 |
Thomas McLain
PSD | President | 66 | 19-07-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Levangie
BRD | Director/Board Member | 74 | 21-08-29 |
Chairman | 72 | 18-03-14 | |
James McCullough
FOU | Founder | 56 | 18-03-14 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 29.69 | -1.04% | 1 275 |
24-04-18 | 30 | 0.00% | 47,266 |
24-04-17 | 30 | -3.23% | 186,607 |
24-04-16 | 31 | -4.62% | 34,497 |
24-04-15 | 32.5 | 0.00% | 110,904 |
Delayed Quote London S.E., April 19, 2024 at 03:03 am EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+88.39% | 48.19M | |
-48.09% | 2.56B | |
+4.82% | 1.66B | |
-12.79% | 1.45B | |
+20.19% | 1.2B | |
-14.90% | 978M | |
-23.61% | 875M | |
-9.43% | 698M | |
-17.46% | 687M | |
+2.36% | 480M |
- Stock Market
- Equities
- RENX Stock